Status:
COMPLETED
Safety & PK of Single Doses of MT1980
Lead Sponsor:
Monument Therapeutics Limited
Collaborating Sponsors:
ICON plc
Conditions:
Neuroinflammatory Response
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
MT1980 is being developed as a treatment for neuroinflammation (an inflammatory response in the brain and/or spinal cord). Much research has focused on the central role of neuroinflammation in the pat...
Eligibility Criteria
Inclusion
- Healthy volunteers with good physical and mental health
- Body Mass Index 18 to 30 kg/m2
- Men \& women of child-bearing potential must agree to use adequate contraception
- Willing \& able to provide written informed consent and to communicate and participate in the study
Exclusion
- Clinically significant abnormal biochemistry, haematology, urinalysis results
- Results of screening liver function or kidney function tests outside of normal ranges
- Heavy daily smoking or use of nicotine containing substances
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 4 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05429840
Start Date
June 1 2022
End Date
October 4 2022
Last Update
November 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icon Early Development Services
Groningen, Netherlands